Lupin Quarterly Results for Trading Insights
In Sept 2025, Lupin (LUPIN) reported revenue ₹6,921 Cr and net profit ₹1,485 Cr — revenue +25.0% YoY. For annual financials, live price and key ratios, visit LUPIN stock overview.
Latest Quarter Net Profit
₹1,485 Cr
QSept 2025
LUPIN Quarterly Results — Revenue, Profit & EPS Highlights
Lupin latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with LUPIN fair value to assess whether the stock is under or overvalued.
- Revenue of ₹6,921 Cr in Sept 2025 (+23.2% vs Mar 2025, +25.0% vs Sept 2024)
- Net Profit of ₹1,485 Cr in Sept 2025 (+89.9% vs Mar 2025, +72.7% vs Sept 2024)
- EBITDA of ₹2,215 Cr in Sept 2025 (+74.0% vs Mar 2025)
- Operating Margin of 31.0% in Sept 2025 (+9.0pp vs Mar 2025)
- Earnings Per Share of ₹32.36 in Sept 2025 (+91.1% vs Mar 2025)
Lupin Quarterly Results — Revenue, EBITDA, Net Profit & EPS
LUPIN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6,921 | 5,619 | 6,243 | 7,215 | 5,539 | 23.2% | 25.0% |
| Net Profit (₹ Cr) | 1,485 | 782 | 1,222 | 1,181 | 860 | - | - |
| EBITDA (₹ Cr) | 2,215 | 1,273 | 1,702 | 1,883 | 1,207 | - | - |
| EPS (₹) | 32.36 | 16.93 | 26.70 | 25.74 | 18.70 | - | - |
| Operating Margin (%) | 31.0% | 22.0% | 26.0% | 25.0% | 21.0% | - | - |
LUPIN Share Price Trend — 1-Year Movement Across Quarterly Results
Lupin 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse LUPIN shareholder distribution to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Dec 2025
7,215
Jun 2025
6,243
Mar 2025
5,619
Sept 2025
6,921
Net Profit Trend (₹ Cr)
Dec 2025
1,181
Jun 2025
1,222
Mar 2025
782
Sept 2025
1,485
Operating Margin Trend (%)
Dec 2025
25.0%
Jun 2025
26.0%
Mar 2025
22.0%
Sept 2025
31.0%
LUPIN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Lupin latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹396,418.12 Cr | 1652.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 127.1 |
|
Divis Laboratories
Sept 2025 |
₹162,373.86 Cr | 6070.0 | 2,860 | 689 | +7.1% | - | 24.1% | 233.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹140,630.85 Cr | 4181.0 | 3,219 | 591 | +11.3% | - | 18.4% | 238.4 |
|
Dr Reddys Laborator…
Sept 2025 |
₹102,844.71 Cr | 1235.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.4 |
|
Cipla
Sept 2025 |
₹99,316.63 Cr | 1211.1 | 7,716 | 1,353 | +12.0% | - | 17.5% | 72.4 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores